Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first choice in rheumatoid arthritis (RA) but response varies. Predicting non-response to MTX could enable earlier access to alternative ...

Source: Arthritis Research and Therapy - July 13, 2018 Category: Rheumatology Authors: Jamie C. Sergeant, Kimme L. Hyrich, James Anderson, Kamilla Kopec-Harding, Holly F. Hope, Deborah P. M. Symmons, Anne Barton and Suzanne M. M. Verstappen Tags: Research article Source Type: research